Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COM701 maintenance therapy trial in platinum-sensitive recurrent ovarian cancer
MOH_2025-04-29_014062Phase 2Recruiting
- Sponsor
- Compugen Ltd.
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing COM701 with Placebo (2 arms). Started Apr 2025; status: recruiting.
02
Drugs
COM701
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2025-04-29_014062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-04-29_014062.